RPS6KB2 and breast carcinoma: While amplification of RPS6KB2 is only associated with 4.3% of breast cancers, a large number of samples (21.3%) exhibit gains, suggesting that RPS6KB2 gain rather than amplification is a major event in breast cancer [21].